Diseases | Free Full-Text | Diagnostic and Prognostic Value of CEA and CA19-9 in Colorectal Cancer | HTML
Ratio of CA19-9 Level to Total Tumor Volume as a Prognostic Predictor of Pancreatic Carcinoma After Curative Resection - Junming Xu, Shaocheng Lyu, Yang Zhao, Xinxue Zhang, Zhe Liu, Xin Zhao, Qiang
Trefoil factor(s) and CA19.9: A promising panel for early detection of pancreatic cancer - eBioMedicine
CA19-9 decrease at 8 weeks as a predictor of overall survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic pancreatic cancer -
Molecules | Free Full-Text | Electrochemical Immunoassay for Tumor Marker CA19-9 Detection Based on Self-Assembled Monolayer
Combining CRP and CA19-9 in a novel prognostic score in pancreatic ductal adenocarcinoma | Scientific Reports
CA19-9 is a significant prognostic marker of patients with stage III gastric cancer - European Journal of Surgical Oncology
Lead-Time Trajectory of CA19-9 as an Anchor Marker for Pancreatic Cancer Early Detection - Gastroenterology
CA19.9 Test : Results, procedures, purpose, & risks - FactDr
The prognostic and predictive value of serum CA19.9 in pancreatic cancer - Annals of Oncology
Comparison of two immunoassays for CA19-9, CEA and AFP tumor markers - Biochemia Medica
CA 19-9 – Pancreatic Cancer Action Network
The glycan CA19-9 promotes pancreatitis and pancreatic cancer in mice | Science
CEA but not CA19-9 is an independent prognostic factor in patients undergoing resection of cholangiocarcinoma | Scientific Reports
Antibodies to a CA 19-9 Related Antigen Complex Identify SOX9 Expressing Progenitor Cells In Human Foetal Pancreas and Pancreatic Adenocarcinoma | Scientific Reports
The glycan CA19-9 promotes pancreatitis and pancreatic cancer in mice | Science
extreme High levels of ca19-9 associated with adenocarcinoma of the lung
CA19-9 Levels in Saliva and Urine of Patients with Ductal Adenocarcinoma of the Pancreas Correlates with Serum CA19-9 Levels - A Prospective Preliminary Study
Evaluation of CEA, CA19-9, CRP and leucocyte count as prognostic marker... | Download Scientific Diagram
CA19-9 decrease at 8 weeks as a predictor of overall survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic pancreatic cancer -